Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Brors

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Leukemia|December 25, 2004
Gene expression profiling of Philadelphia chromosome (Ph)-negative CD34+ hematopoietic stem and progenitor cells of patients with Ph-positive CML in major molecular remission during therapy with imatinibF Neumann, N Teutsch, S Kliszewski, et al.
Leukemia|January 26, 2007
Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phaseE Diaz-Blanco, I Bruns, F Neumann, et al.
Leukemia|January 23, 2009
The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescenceI Bruns, A Czibere, J C Fischer, et al.
Der Pathologe|August 17, 2010
[Molecular pathology of sarcomas. Update on the research group "Molecular Diagnosis of Sarcomas"]A V Rüsseler, B Brors, T Fischer, et al.
Leukemia|November 20, 2015
Cooperation of BRAF(F595L) and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signalingM Kordes, M Röring, C Heining, et al.
Translational Psychiatry|August 20, 2014
Investigation of manic and euthymic episodes identifies state- and trait-specific gene expression and STAB1 as a new candidate gene for bipolar disorderS H Witt, D Juraeva, C Sticht, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2016
Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinomaS M Dieter, C Heining, A Agaimy, et al.
ESMO Open|November 22, 2021
Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trialC E Heilig, P Horak, S Kreutzfeldt, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|June 18, 2016
Genome-wide association study of pathological gamblingM Lang, T Leménager, F Streit, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
17.6% of patients in a German cohort with exocrine pancreatic cancer were diagnosed with a genetic tumor syndrome-a case for universal genetic testing?D William, M Bermúdez, A Kübler, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Leukemia|December 25, 2004
Gene expression profiling of Philadelphia chromosome (Ph)-negative CD34+ hematopoietic stem and progenitor cells of patients with Ph-positive CML in major molecular remission during therapy with imatinibF Neumann, N Teutsch, S Kliszewski, et al.
Leukemia|January 26, 2007
Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phaseE Diaz-Blanco, I Bruns, F Neumann, et al.
Leukemia|January 23, 2009
The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescenceI Bruns, A Czibere, J C Fischer, et al.
Der Pathologe|August 17, 2010
[Molecular pathology of sarcomas. Update on the research group "Molecular Diagnosis of Sarcomas"]A V Rüsseler, B Brors, T Fischer, et al.
Leukemia|November 20, 2015
Cooperation of BRAF(F595L) and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signalingM Kordes, M Röring, C Heining, et al.
Translational Psychiatry|August 20, 2014
Investigation of manic and euthymic episodes identifies state- and trait-specific gene expression and STAB1 as a new candidate gene for bipolar disorderS H Witt, D Juraeva, C Sticht, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2016
Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinomaS M Dieter, C Heining, A Agaimy, et al.
ESMO Open|November 22, 2021
Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trialC E Heilig, P Horak, S Kreutzfeldt, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|June 18, 2016
Genome-wide association study of pathological gamblingM Lang, T Leménager, F Streit, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
17.6% of patients in a German cohort with exocrine pancreatic cancer were diagnosed with a genetic tumor syndrome-a case for universal genetic testing?D William, M Bermúdez, A Kübler, et al.
Pageof 4